In this project, we want to selectively target T-cell malignancies using antibodies. To combat the heterogeneity present in these malignancies, we’re aiming to selectively target a combination of cell-surface proteins specific to tumor cells. To ensure high avidity binding when all ligands are expressed, single-chain variable fragments (scFvs) will be used that display reduced affinity for its respective antigen. These scFvs will be assembled on a synthetic scaffold based on Gramicidin S to create a multivalent display. The use of bioorthogonal chemistry for the coupling will allow a variety of scFVs to be displayed with relative ease.